Wells Fargo
KRSA

Wells Fargo’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Wells Fargo’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2
Closed -$48 – 7020
2024
Q1 		$48 Hold
2
– – ﹤0.01% 6839
2023
Q4 		$50 Hold
2
– – ﹤0.01% 6930
2023
Q3 		$48 Hold
2
– – ﹤0.01% 6925
2023
Q2 		$58 Hold
2
– – ﹤0.01% 7018
2023
Q1 		$118 Sell
2
-15
-88% -$189 ﹤0.01% 6901
2022
Q4 		$1.55K Buy
17
+14
+467% +$166 ﹤0.01% 6067
2022
Q3 		$0 Hold
3
– – ﹤0.01% 6756
2022
Q2 		$0 Hold
3
– – ﹤0.01% 6900
2022
Q1 		$0 Hold
3
– – ﹤0.01% 7162
2021
Q4 		$0 Hold
3
– – ﹤0.01% 7298
2021
Q3 		$1K Buy
3
+1
+50% +$65 ﹤0.01% 6680
2021
Q2 		$1K Sell
2
-54
-96% -$3.38K ﹤0.01% 6639
2021
Q1 		$21K Sell
56
-305
-84% -$22.9K ﹤0.01% 6128
2020
Q4 		$154K Buy
361
+158
+78% +$10.8K ﹤0.01% 5191
2020
Q3 		$173K Sell
203
-45
-18% -$5.14K ﹤0.01% 5023
2020
Q2 		$205K Sell
248
-144
-37% -$12K ﹤0.01% 4892
2020
Q1 		$145K Buy
392
+81
+26% +$5.78K ﹤0.01% 4869
2019
Q4 		$118K Sell
311
-114
-27% -$10.6K ﹤0.01% 5218
2019
Q3 		$722K Buy
425
+171
+67% +$36.9K ﹤0.01% 4101
2019
Q2 		$408K Buy
+254
New +$71.9K ﹤0.01% 4519

Other funds holding KRSA

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo's KRSA Position: Q2 2024 in Review

Wells Fargo sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q2 2024, closing a stake of 2 shares — an estimated $48 sold.

Wells Fargo first reported a position in KRSA in Q2 2019 and held it in 20 quarters. The position peaked at $722K in Q3 2019. 15 funds tracked by Wall St. Rank hold KRSA as of Q2 2024.

  • Wells Fargo reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 2 Korsana Biosciences, Inc. Common Stock shares in Q2 2024, an estimated $48.
  • Wells Fargo first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
  • Wells Fargo's Korsana Biosciences, Inc. Common Stock position peaked at $722K in Q3 2019.
  • 15 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.